Complement anaphylatoxins as immune regulators in cancer

Cancer Medicine

Volumn 3, Issue 4, 2014, Pages 747-758

  Sayegh, Eli T ^a   Bloch, Orin ^a   Parsa, Andrew T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anaphylatoxins; Cancer; Complement; Immune; Microenvironment

Indexed keywords

COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; UNCLASSIFIED DRUG; ANAPHYLATOXIN;

BREAST CANCER; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER MODEL; CELL COMPOSITION; CELL FUNCTION; EFFECTOR CELL; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LUNG CANCER; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYSTEMATIC REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; ANIMAL; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANAPHYLATOXINS; ANIMALS; HUMANS; IMMUNOMODULATION; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84916231498     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.241     Document Type: Review

References (95)

1. Markiewski, M. M., and J. D. Lambris . 2009. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 30:286-292. doi: 10.1016/j.it.2009.04.002.
2. Markiewski, M. M., R. A. DeAngelis, F. Benencia, S. K. Ricklin-Lichtsteiner, A. Koutoulaki, C. Gerard, et al. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9:1225-1235. doi: 10.1038/ni.1655.
3. Loveland, B. E., and J. Cebon . 2008. Cancer exploiting complement: a clue or an exception? Nat. Immunol. 9:1205-1206. doi: 10.1038/ni1108-1205.
4. Ostrand-Rosenberg, S. 2008. Cancer and complement. Nat. Biotechnol. 26:1348-1349. doi: 10.1038/nbt1208-1348.
5. Rutkowski, M. J., M. E. Sughrue, A. J. Kane, S. A. Mills, and A. T. Parsa . 2010. Cancer and the complement cascade. Mol. Cancer Res. 8:1453-1465. doi: 10.1158/1541-7786.MCR-10-0225.
6. Markiewski, M. M., and J. D. Lambris . 2007. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171:715-727. doi: 10.2353/ajpath.2007.070166.
7. Carroll, M. C. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5:981-986. doi: 10.1038/ni1113.
8. Zhou, W. 2012. The new face of anaphylatoxins in immune regulation. Immunobiology 217:225-234. doi: 10.1016/j.imbio.2011.07.016.
9. Klos, A., A. J. Tenner, K.-O. Johswich, R. R. Ager, E. S. Reis, and J. Köhl . 2009. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46:2753-2766. doi: 10.1016/j.molimm.2009.04.027.
10. Guo, R.-F., and P. A. Ward . 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23:821-852. doi: 10.1146/annurev.immunol.23.021704.115835.
11. Markiewski, M. M., R. A. DeAngelis, and J. D. Lambris . 2006. Liver inflammation and regeneration: two distinct biological phenomena or parallel pathophysiologic processes? Mol. Immunol. 43:45-56. doi: 10.1016/j.molimm.2005.06.019.
12. Reca, R., D. Mastellos, M. Majka, L. Marquez, J. Ratajczak, S. Franchini, et al. 2003. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood 101:3784-3793. doi: 10.1182/blood-2002-10-3233.
13. Nozaki, M., B. J. Raisler, E. Sakurai, J. V. Sarma, S. R. Barnum, J. D. Lambris, et al. 2006. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl. Acad. Sci. USA 103:2328-2333. doi: 10.1073/pnas.0408835103.
14. Fukuoka, Y., H.-Z. Xia, L. B. Sanchez-Muñoz, A. L. Dellinger, L. Escribano, and L. B. Schwartz . 2008. Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5. J. Immunol. 180:6307-6316. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2645414&tool=pmcentrez&rendertype=abstract (accessed 18 June 2013).
15. Huber-Lang, M., J. V. Sarma, F. S. Zetoune, D. Rittirsch, T. A. Neff, S. R. McGuire, et al. 2006. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12:682-687. doi: 10.1038/nm1419.
16. Whiteside, T. L. 2008. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27:5904-5912. doi: 10.1038/onc.2008.271.
17. Denko, N. C., L. A. Fontana, K. M. Hudson, P. D. Sutphin, S. Raychaudhuri, R. Altman, et al. 2003. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22:5907-5914. doi: 10.1038/sj.onc.1206703.
18. Chang, C.-C., M. Campoli, and S. Ferrone . 2005. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv. Cancer Res. 93:189-234. doi: 10.1016/S0065-230X(05)93006-6.
19. Gallucci, S., and P. Matzinger . 2001. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13:114-119. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11154927 (accessed 13 December 2013).
20. Caso, R., R. Silvera, R. Carrio, V. Iragavarapu-Charyulu, R. R. Gonzalez-Perez, and M. Torroella-Kouri . 2010. Blood monocytes from mammary tumor-bearing mice: early targets of tumor-induced immune suppression?Int. J. Oncol. 37:891-900. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20811711 (accessed 18 June 2013).
21. Sica, A., and V. Bronte . 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117:1155-1166. doi: 10.1172/JCI31422.
22. Gallina, G., L. Dolcetti, P. Serafini, C. De Santo, I. Marigo, M. P. Colombo, et al. 2006. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116:2777-2790. doi: 10.1172/JCI28828.
23. Donin, N., K. Jurianz, L. Ziporen, S. Schultz, M. Kirschfink, and Z. Fishelson . 2003. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin. Exp. Immunol. 131:254-263. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1808622&tool=pmcentrez&rendertype=abstract (accessed 9 February 2014).
24. Pio, R., D. Ajona, and J. D. Lambris . 2013. Complement inhibition in cancer therapy. Semin. Immunol. 25:54-64. doi: 10.1016/j.smim.2013.04.001.
25. Jurianz, K., S. Ziegler, H. Garcia-Schüler, S. Kraus, O. Bohana-Kashtan, Z. Fishelson, et al. 1999. Complement resistance of tumor cells: basal and induced mechanisms. Mol. Immunol. 36:929-939. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10698347 (accessed 9 February 2014.
26. Fishelson, Z., N. Donin, S. Zell, S. Schultz, and M. Kirschfink . 2003. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40:109-123. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12914817 (accessed 9 February 2014).
27. Varela, J. C., M. Imai, C. Atkinson, R. Ohta, M. Rapisardo, and S. Tomlinson . 2008. Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res. 68:6734-6742. doi: 10.1158/0008-5472.CAN-08-0502.
28. Zell, S., N. Geis, R. Rutz, S. Schultz, T. Giese, and M. Kirschfink . 2007. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin. Exp. Immunol. 150:576-584. doi: 10.1111/j.1365-2249.2007.03507.x.
29. Watson, N. F. S., L. G. Durrant, Z. Madjd, I. O. Ellis, J. H. Scholefield, and I. Spendlove . 2006. Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol. Immunother. 55:973-980. doi: 10.1007/s00262-005-0055-0.
30. Macor, P., and F. Tedesco . 2007. Complement as effector system in cancer immunotherapy. Immunol. Lett. 111:6-13. doi: 10.1016/j.imlet.2007.04.014.
31. Swann, J. B., and M. J. Smyth . 2007. Immune surveillance of tumors. J. Clin. Invest. 117:1137-1146. doi: 10.1172/JCI31405.
32. Loukinova, E., G. Dong, I. Enamorado-Ayalya, G. R. Thomas, Z. Chen, H. Schreiber, et al. 2000. Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19:3477-3486. doi: 10.1038/sj.onc.1203687.
33. Curiel, T. J. 2007. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117:1167-1174. doi: 10.1172/JCI31202.
34. Nagaraj, S., and D. I. Gabrilovich . 2008. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 68:2561-2563. doi: 10.1158/0008-5472.CAN-07-6229.
35. Gabrilovich, D. I., and S. Nagaraj . 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-174. doi: 10.1038/nri2506.
36. Kolev, M., L. Towner, and R. Donev . 2011. Complement in cancer and cancer immunotherapy. Arch. Immunol. Ther. Exp. (Warsz) 59:407-419. doi: 10.1007/s00005-011-0146-x.
37. Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg . 2005. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65:11743-11751. doi: 10.1158/0008-5472.CAN-05-0045.
38. Glovsky, M. M., T. E. Hugli, T. Ishizaka, L. M. Lichtenstein, and B. W. Erickson . 1979. Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release. J. Clin. Invest. 64:804-811. doi: 10.1172/JCI109527.
39. Daffern, P. J., P. H. Pfeifer, J. A. Ember, and T. E. Hugli . 1995. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J. Exp. Med. 181:2119-2127. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2192052&tool=pmcentrez&rendertype=abstract (accessed 13 December 2013).
40. Klos, A., S. Bank, C. Gietz, W. Bautsch, J. Köhl, M. Burg, et al. 1992. C3a receptor on dibutyryl-cAMP-differentiated U937 cells and human neutrophils: the human C3a receptor characterized by functional responses and 125I-C3a binding. Biochemistry. 31:11274-11282. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1332754 (accessed 13 December 2013).
41. Zwirner, J., T. Werfel, H. C. Wilken, E. Theile, and O. Götze . 1998. Anaphylatoxin C3a but not C3a(desArg) is a chemotaxin for the mouse macrophage cell line J774. Eur. J. Immunol. 28:1570-1577. doi: 10.1002/(SICI)1521-4141(199805)28:05%3c1570:AID-IMMU1570%3e3.0.CO;2-6.
42. Zwirner, J., O. Götze, A. Sieber, A. Kapp, G. Begemann, T. Zuberbier, et al. 1998. The human mast cell line HMC-1 binds and responds to C3a but not C3a(desArg). Scand. J. Immunol. 47:19-24. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9467653 (accessed 13 December 2013).
43. Gutzmer, R., M. Lisewski, J. Zwirner, S. Mommert, C. Diesel, M. Wittmann, et al. 2004. Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons. Immunology 111:435-443. doi: 10.1111/j.1365-2567.2004.01829.x.
44. Bamberg, C. E., C. R. Mackay, H. Lee, D. Zahra, J. Jackson, Y. S. Lim, et al. 2010. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J. Biol. Chem. 285:7633-7644. doi: 10.1074/jbc.M109.092106.
45. Chenoweth, D. E., and T. E. Hugli . Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc. Natl. Acad. Sci. USA 1978;75:3943-3947. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=392905&tool=pmcentrez&rendertype=abstract (accessed 13 December 2013).
46. Chenoweth, D. E., and M. G. Goodman . 1983. The C5a receptor of neutrophils and macrophages. Agents Actions Suppl. 12:252-273. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6573117 (accessed 13 December 2013).
47. Gerard, N. P., M. K. Hodges, J. M. Drazen, P. F. Weller, and C. Gerard . 1989. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J. Biol. Chem. 264:1760-1766. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2912983 (accessed 13 December 2013).
48. Werfel, T., M. Oppermann, G. Begemann, O. Götze, and J. Zwirner . 1997. C5a receptors are detectable on mast cells in normal human skin and in psoriatic plaques but not in weal and flare reactions or in uticaria pigmentosa by immunohistochemistry. Arch. Dermatol. Res. 289:83-86. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9049041 (accessed 13 December 2013).
49. Morelli, A., A. Larregina, I. Chuluyán, E. Kolkowski, and L. Fainboim . 1996. Expression and modulation of C5a receptor (CD88) on skin dendritic cells. Chemotactic effect of C5a on skin migratory dendritic cells. Immunology. 89:126-134. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1456660&tool=pmcentrez&rendertype=abstract (accessed 13 December 2013).
50. Peng, Q., K. Li, K. Anderson, C. A. Farrar, B. Lu, R. A. Smith, et al. 2008. Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Blood 111:2452-2461. doi: 10.1182/blood-2007-06-095018.
51. Li, K., K. J. Anderson, Q. Peng, A. Noble, B. Lu, A. P. Kelly, et al. 2008. Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Blood 112:5084-5094. doi: 10.1182/blood-2008-05-156646.
52. Zhou, W., H. Patel, K. Li, Q. Peng, M.-B. Villiers, and S. H. Sacks . 2006. Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. Blood 107:2461-2469. doi: 10.1182/blood-2005-08-3144.
53. Soruri, A., S. Kim, Z. Kiafard, and J. Zwirner . 2003. Characterization of C5aR expression on murine myeloid and lymphoid cells by the use of a novel monoclonal antibody. Immunol. Lett. 88:47-52. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12853161 (accessed 21 June 2013).
54. Strainic, M. G., J. Liu, D. Huang, F. An, P. N. Lalli, N. Muqim, et al. 2008. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28:425-435. doi: 10.1016/j.immuni.2008.02.001.
55. Peng, Q., K. Li, N. Wang, Q. Li, E. Asgari, B. Lu, et al. 2009. Dendritic cell function in allostimulation is modulated by C5aR signaling. J. Immunol. 183:6058-6068. doi: 10.4049/jimmunol.0804186.
56. Nataf, S., N. Davoust, R. S. Ames, and S. R. Barnum . 1999. Human T cells express the C5a receptor and are chemoattracted to C5a. J. Immunol. 162:4018-4023. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10201923 (accessed 13 December 2013).
57. Connelly, M. A., R. A. Moulton, A. K. Smith, D. R. Lindsey, M. Sinha, R. A. Wetsel, et al. 2007. Mycobacteria-primed macrophages and dendritic cells induce an up-regulation of complement C5a anaphylatoxin receptor (CD88) in CD3+ murine T cells. J. Leukoc. Biol. 81:212-220. doi: 10.1189/jlb.1005582.
58. Lalli, P. N., M. G. Strainic, M. Yang, F. Lin, M. E. Medof, and P. S. Heeger . 2008. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112:1759-1766. doi: 10.1182/blood-2008-04-151068.
59. Weaver, D. J., Jr., E. S. Reis, M. K. Pandey, G. Köhl, N. Harris, C. Gerard, et al. 2010. C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur. J. Immunol. 40:710-721. doi: 10.1002/eji.200939333.
60. Heeger, P. S., P. N. Lalli, F. Lin, A. Valujskikh, J. Liu, N. Muqim, et al. 2005. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201:1523-1530. doi: 10.1084/jem.20041967.
61. Fang, C., X. Zhang, T. Miwa, and W.-C. Song . 2009. Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. Blood 114:1005-1015. doi: 10.1182/blood-2009-01-198283.
62. Hashimoto, M., K. Hirota, H. Yoshitomi, S. Maeda, S. Teradaira, S. Akizuki, et al. 2010. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J. Exp. Med. 207:1135-1143. doi: 10.1084/jem.20092301.
63. Murphy, K. M., and B. Stockinger . 2010. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat. Immunol. 11:674-680. doi: 10.1038/ni.1899.
64. Heeger, P. S., and C. Kemper . 2012. Novel roles of complement in T effector cell regulation. Immunobiology 217:216-224. doi: 10.1016/j.imbio.2011.06.004.
65. Dunkelberger, J. R., and W.-C. Song . 2010. Role and mechanism of action of complement in regulating T cell immunity. Mol. Immunol. 47:2176-2186. doi: 10.1016/j.molimm.2010.05.008.
66. Köhl, J., and M. Wills-Karp . 2007. Complement regulates inhalation tolerance at the dendritic cell/T cell interface. Mol. Immunol. 44:44-56. doi: 10.1016/j.molimm.2006.06.016.
67. Karp, C. L., A. Grupe, E. Schadt, S. L. Ewart, M. Keane-Moore, P. J. Cuomo, et al. 2000. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat. Immunol. 1:221-226. doi: 10.1038/79759.
68. Peng, T., L. Hao, J. A. Madri, X. Su, J. A. Elias, G. L. Stahl, et al. 2005. Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response. J. Clin. Invest. 115:1590-1600. doi: 10.1172/JCI22906.
69. Hawlisch, H., Y. Belkaid, R. Baelder, D. Hildeman, C. Gerard, and J. Köhl . 2005. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 22:415-426. doi: 10.1016/j.immuni.2005.02.006.
70. Drouin, S. M., D. B. Corry, T. J. Hollman, J. Kildsgaard, and R. A. Wetsel . 2002. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J. Immunol. 169:5926-5933. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12421977 (accessed 20 June 2013).
71. Drouin, S. M., M. Sinha, G. Sfyroera, J. D. Lambris, and R. A. Wetsel . 2006. A protective role for the fifth complement component (c5) in allergic airway disease. Am. J. Respir. Crit. Care Med. 173:852-857. doi: 10.1164/rccm.200503-334OC.
72. Köhl, J., R. Baelder, I. P. Lewkowich, M. K. Pandey, H. Hawlisch, L. Wang, et al. 2006. A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J. Clin. Invest. 116:783-796. doi: 10.1172/JCI26582.
73. Kawamoto, S., A. Yalcindag, D. Laouini, S. Brodeur, P. Bryce, B. Lu, et al. 2004. The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen. J. Clin. Invest. 114:399-407. doi: 10.1172/JCI19082.
74. Nunez-Cruz, S., P. A. Gimotty, M. W. Guerra, D. C. Connolly, Y. Q. Wu, R. A. DeAngelis, et al. 2012. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14:994-1004. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3514739&tool=pmcentrez&rendertype=abstract (accessed 18 June 2013).
75. Gunn, L., C. Ding, M. Liu, Y. Ma, C. Qi, Y. Cai, et al. 2012. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J. Immunol. 189:2985-2994. doi: 10.4049/jimmunol.1200846.
76. Corrales, L., D. Ajona, S. Rafail, J. J. Lasarte, J. I. Riezu-Boj, J. D. Lambris, et al. 2012. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J. Immunol. 189:4674-4683. doi: 10.4049/jimmunol.1201654.
77. Cao, X. 2010. Regulatory T cells and immune tolerance to tumors. Immunol. Res. 46:79-93. doi: 10.1007/s12026-009-8124-7.
78. Fuenmayor, J., K. Perez-Vazquez, D. Perez-Witzke, M. L. Penichet, and R. F. Montano . 2010. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg. Mol. Cancer Ther. 9:2175-2185. doi: 10.1158/1535-7163.MCT-09-1054.
79. Keler, T., R. F. Graziano, A. Mandal, P. K. Wallace, J. Fisher, P. M. Guyre, et al. 1997. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. Cancer Res. 57:4008-4014. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9307286 (accessed 10 February 2014).
80. Ostrand-Rosenberg, S. 2004. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr. Opin. Immunol. 16:143-150. doi: 10.1016/j.coi.2004.01.003.
81. Pagès, F., J. Galon, M.-C. Dieu-Nosjean, E. Tartour, C. Sautès-Fridman, and W.-H. Fridman . 2010. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29:1093-1102. doi: 10.1038/onc.2009.416.
82. Pagès, F., A. Berger, M. Camus, F. Sanchez-Cabo, A. Costes, R. Molidor, et al. 2005. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353:2654-2666. doi: 10.1056/NEJMoa051424.
83. Galon, J., A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964. doi: 10.1126/science.1129139.
84. Stewart, T. H., and S. C. Tsai . 1993. The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer. Clin. Exp. Metastasis 11:295-305. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8319378 (accessed 19 June 2013).
85. Sheu, B. C., S. M. Hsu, H. N. Ho, R. H. Lin, P. L. Torng, and S. C. Huang . 1999. Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. Cancer. 86:1537-1543. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10526283 (accessed 19 June 2013).
86. Nakano, O., M. Sato, Y. Naito, K. Suzuki, S. Orikasa, M. Aizawa, et al. 2001. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61:5132-5136. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11431351 (accessed 19 June 2013).
87. Nitta, H., Y. Wada, Y. Kawano, Y. Murakami, A. Irie, K. Taniguchi, et al. 2013. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin. Cancer Res. 19:2004-2013. doi: 10.1158/1078-0432.CCR-12-1204.
88. Ornellas, P., A. A. Ornellas, C. Chinello, E. Gianazza, V. Mainini, M. Cazzaniga, et al. 2012. Downregulation of C3 and C4A/B complement factor fragments in plasma from patients with squamous cell carcinoma of the penis. Int. Braz. J. Urol. 38:739-749. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23302412 (accessed 8 February 2014).
89. Campos, M. M., M. H. de Souza, V. Pires, M. A. Scheiner, E. B. Esteves, and A. A. Ornellas . 1998. Clinical implications of natural killer cytotoxicity in patients with squamous cell carcinoma of the penis. Nat. Immun. 16:256-262. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11061593 (accessed 8 February 2014).
90. Afonso, L. A., N. Moyses, G. Alves, A. A. Ornellas, M. R. Passos, H. Oliveira Ldo, et al. 2012. Prevalence of human papillomavirus and Epstein-Barr virus DNA in penile cancer cases from Brazil. Mem. Inst. Oswaldo Cruz. 107:18-23. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22310531 (accessed 10 February 2014).
91. Campo, M. S., S. V. Graham, M. S. Cortese, G. H. Ashrafi, E. H. Araibi, E. S. Dornan, et al. 2010. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407:137-142. doi: 10.1016/j.virol.2010.07.044.
92. Morin, P. J., J. M. Trent, and F. S. Collins, and B. Vogelstein . 2012. Cancer genetics. D. L. Longo, A. S. Fauci, D. L. Kasper, S. L. Hauser, J. Jameson and J. Loscalzo, eds. Harrison's principles of internal medicine, 18th ed. McGraw-Hill, New York, NY. . Available at: http://accessmedicine.mhmedical.com/content.aspx?bookid=331&Sectionid=40726819 (accessed 8 February 2014).
93. Gelderman, K. A., P. J. K. Kuppen, W. Bruin, G. J. Fleuren, and A. Gorter . 2002. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur. J. Immunol. 32:128-135. doi: 10.1002/1521-4141(200201)32:1%3c128:AID-IMMU128%3e3.0.CO;2-P.
94. Sier, C. F. M., K. A. Gelderman, F. A. Prins, and A. Gorter . 2004. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. Int. J. Cancer 109:900-908. doi: 10.1002/ijc.20029.
95. Ziller, F., P. Macor, R. Bulla, D. Sblattero, R. Marzari, and F. Tedesco . 2005. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur. J. Immunol. 35:2175-2183. doi: 10.1002/eji.200425920.